Nutriventia lands strategic growth investment from NDude Labs

Nutriventia has secured a strategic growth investment from NDude Labs to expand clinical research, scale its branded ingredients portfolio and prepare for U.S. commercial operations. The Mumbai-based nutraceutical ingredients company is positioning the deal as fuel for global expansion across Europe and Asia-Pacific.

Why it matters: - The investment gives Nutriventia capital to push clinically validated nutraceutical ingredients into more global markets. - The funding supports a business model built on science-backed claims, a point of differentiation as brands and consumers demand more proof. - Nutriventia plans to use the capital to strengthen its U.S. presence before moving deeper into Europe and Asia-Pacific.

What happened: - Nutriventia Private Limited closed a strategic growth investment from NDude Labs, a strategic investment firm. - The company announced the deal on Sept. 18, 2026, from Mumbai, India. - Nutriventia describes itself as a science-led Indian nutraceutical ingredients company focused on clinically validated, proprietary branded ingredients. - NDude Labs is an investment holding company and operating partner focused on healthcare and wellness businesses.

The details: - The capital will fund deeper clinical R&D at Nutriventia. - Nutriventia will expand its branded ingredients portfolio, including TurmXTRA, CaffXtend, C-Fence, Melotime, Ashwanova (Prolanza), and ALAXTRA. - The company will scale its proprietary E.D.G.E. low-dose delivery platform for next-generation actives. - Nutriventia will build a senior U.S. commercial team. - The company plans to expand into Europe and APAC. - Nutriventia will also increase its scientific communication and thought leadership in key global markets. - The company says its proprietary delivery platforms were built to address bioavailability, stability and dosing efficacy challenges. - Nutriventia says NDude Labs recognized that its intellectual property is built on hard evidence rather than marketing narratives. - NDude Labs said it sees Nutriventia as a science-led, innovation-driven business with the potential to become a global category leader. - NDude Labs said its operating experience, India-U.S. relationships and AI-native approach can help accelerate Nutriventia’s growth.

Between the lines: - The deal underscores investor interest in nutraceutical companies that can show clinical support, patents and proprietary delivery technology. - Nutriventia is trying to compete more like a pharmaceutical-style science company than a traditional supplement ingredient supplier. - NDude Labs appears to be offering more than capital, with a role that includes operating support and market access.

What's next: - Nutriventia will use the new capital to accelerate clinical development and commercial expansion. - The company will establish direct leadership in the U.S. as a base for wider international growth. - Nutriventia plans to deliver its clinically validated branded ingredients to wellness brands worldwide. - The company has support from Investec as financial advisor, with Cyril Amarchand Mangaldas and Stratage Law Partners as legal counsel and PwC as due diligence advisor. - Nutriventia says it has more than 40 years of pharmaceutical-grade expertise, 50-plus studies, 23 clinical studies, 19 peer-reviewed publications, 13 granted global patents and a presence in more than 28 countries. - More information is available on Nutriventia’s LinkedIn page and the company’s YouTube channel.

The bottom line: - Nutriventia is using new capital to turn clinical validation and proprietary delivery technology into a broader international commercial push.